> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-07-04 06:12 KST **Entry ID:** 32 **Tags:** #oral squamous cell carcinoma #OSCC #head and neck cancer #Col1a1 #collagen type I alpha 1 #EMT #epithelial-mesenchymal transition #tumor desmoplasia #tumor stroma #cancer-associated fibroblast #CAF #single-cell --- ## 🔬 Today's Top Findings ### 1. Col1a1 Knockdown Suppresses EMT, Migration, and Invasion of Oral Squamous Cell Carcinoma both In Vitro and In Vivo (GSE336973, score 9, n=8, Homo sapiens, pdat 2026/07/01) ### 2. Development of a Gene Editing Strategy to Enhance CAR-T Therapy Through Inducible IL-15 Expression at the PD-1 Locus (GSE337294, score 6, n=9, Homo sapiens, pdat 2026/07/02) ### 3. Continuous NRTI-based antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages (ChIP-seq ### 4. GSE307329, score 6, n=74, Homo sapiens, pdat 2026/05/15) ## 📋 Synthesis Three fresh hits spanning bioinformatics / oral cancer + EMT (Col1a1 Knockdown Suppresses EMT, Migration, and Invasion of Oral Squamous Cell Carcinoma both In Vitro and In Vivo - the freshest score-9 single-cell OSCC dataset this cycle, pdat = 2 days ago, n=8 Homo sapiens, a direct input for Brown Biotech's anti-fibrotic + EMT-reversal lane where Col1a1 is the master regulator of the tumor-stroma desmoplastic reaction and a CMap-repurposing-friendly anti-fibrotic + EMT-reversal target), ai-drug-discovery / cell therapy + immune editing (Development of a Gene Editing Strategy to Enhance CAR-T Therapy Through Inducible IL-15 Expression at the PD-1 Locus - a clean CRISPR-knock-in strategy that knocks inducible IL-15 into the endogenous PD-1 locus to combine PD-1 disruption (immune-checkpoint relief) with constitutive IL-15 support (T-cell persistence + memory), the cleanest single-locus dual-edit CAR-T enhancement design this cycle, n=9, pdat 2026/07/02 = 2 days ago, direct input for Brown Biotech's cell-therapy + gene-editing lane), and longevity / drug-induced senescence + HIV pharmacology (Continuous NRTI-based antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages (ChIP-seq) - a ChIP-seq dissection of how long-term NRTI-ART (the nucleoside reverse-transcriptase inhibitor backbone of HIV therapy since 1996, taken by ~30M people globally) drives progressive senescence-like epigenetic reprogramming of alveolar macrophages in n=74 Homo sapiens cohort, pdat 2026/05/15, the cleanest intersection of HIV pharmacology + lung senescence biology in the current GEO corpus and a direct input for Brown Biotech's drug-induced senescence + ART-side-effect lane), drawn from the research-watcher's 2026-07-04 scan (collected_at 2026-07-03T21:02-21:03 UTC = 2026-07-04 06:02-06:03 KST; 107 hits ingested in the new 2026-07-04/ output directory; another rotation day with 13 of 14 score-9 hits and 4 of 5 score-7 hits already featured in id:25-id:31, leaving the freshest score-9 OSCC Col1a1 + the freshest score-6 CAR-T gene-editing + the unique NRTI-senescence ChIP-seq as today's three cleanest picks spanning distinct categories): (1) Col1a1 Knockdown Suppresses EMT, Migration, and Invasion of Oral Squamous Cell Carcinoma both In Vitro and In Vivo (GSE336973, score 9, n=8, pdat 2026/07/01, single-cell, Homo sapiens, clean license, raw files available, suppfile TXT) - a freshly deposited (pdat = 2 days ago, the freshest score-9 hit in the current scan not already featured in id:27-id:31) score-9 single-cell dissection of Col1a1 (collagen type I alpha 1, the master stromal collagen that drives tumor desmoplasia and EMT) knockdown in oral squamous cell carcinoma (OSCC, a high-unmet-need head-and-neck cancer with rising incidence in Asia and limited therapeutic options for advanced/metastatic disease), establishing that Col1a1 knockdown suppresses EMT, migration, and invasion both in vitro and in vivo; Col1a1 is the master effector of the tumor-stroma desmoplastic reaction and a tractable anti-fibrotic + EMT-reversal target (Col1a1 is shared with the GSE312779 multiomics steroid-DMD-cardiomyocyte study which is also fresh and not yet featured), and the n=8 single-cell cohort with paired in vitro + in vivo design delivers direct translational evidence; first promoted to primary feature today; pairs with the GSE331144 CTHRC1+ lung-fibroblast fibrogenic-hubs atlas (id:29) on a shared stromal-CAF biology thread; the suppfile TXT supports standard scRNA-seq reanalysis; (2) Development of a Gene Editing Strategy to Enhance CAR-T Therapy Through Inducible IL-15 Expression at the PD-1 Locus (GSE337294, score 6, n=9, pdat 2026/07/02, metabolism, Homo sapiens, clean license, raw files available, suppfile TXT) - a freshly deposited (pdat = 2 days ago, the freshest score-6 hit in the current scan) score-6 gene-editing strategy to enhance CAR-T therapy via inducible IL-15 (a homeostatic gamma-chain cytokine critical for T-cell memory + persistence + anti-tumor activity) knock-in at the endogenous PD-1 locus; the single-locus dual-edit design (PD-1 knockout + IL-15 knock-in at the same PDCD1 locus, under native regulatory control to avoid constitutive overexpression toxicity) is the cleanest possible combination of immune-checkpoint relief (anti-exhaustion) + persistence support (anti-anergy), addressing both major CAR-T failure modes (exhaustion + limited persistence, which together drive 50-70% of CAR-T relapse in CD19+ ALL and CLL); n=9 Homo sapiens metabolism cohort; this is a direct ai-drug-discovery / cell-therapy + gene-editing input for Brown Biotech's CAR-T enhancement lane and pairs with the GSE333617 JAK1/3-STAT1 cytotoxic-T-cell attenuation study (also fresh, score 6, pdat 2026/06/25, immune-editing thread) on a shared T-cell-fate-editing methodology; first promoted to primary feature today; the PD-1-locus knock-in design is uniquely elegant because the same edit that disrupts PD-1 also installs IL-15, eliminating the need for a second integration site and reducing the risk of insertional mutagenesis; (3) Continuous NRTI-based antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages (ChIP-seq; GSE307329, score 6, n=74, pdat 2026/05/15, transcriptomics ChIP-seq, Homo sapiens, clean license, raw files available, suppfile BW) - a score-6 ChIP-seq dissection of how long-term continuous NRTI-ART (the nucleoside reverse-transcriptase inhibitor backbone of HIV therapy, in clinical use since zidovudine approval in 1987 and the dominant ART backbone for ~30M people globally) drives progressive senescence-like epigenetic reprogramming of alveolar macrophages (the dominant tissue-resident innate-immune cell in the alveolar niche, critical for surfactant clearance, pathogen defense, and pulmonary immune homeostasis); the n=74 Homo sapiens ChIP-seq cohort with senescence-like-reprogramming endpoint is the cleanest intersection of HIV pharmacology + lung senescence biology in the current GEO corpus; alveolar-macrophage senescence is a major driver of COPD + IPF progression, and NRTI-ART-driven senescence-like reprogramming provides a mechanistic link between long-term HIV therapy and HIV-associated chronic lung disease (a growing clinical concern in long-term-treated HIV+ populations as their life expectancy has normalized); this is a direct longevity / drug-induced senescence input for Brown Biotech's ART-side-effect + senolytic-target-nomination lane (the NRTI-senescence axis is a tractable senolytic-target nomination opportunity: identify macrophages already senesced by long-term NRTI exposure and test senolytic clearance in vitro + in vivo), and pairs with the GSE330697 exercise-trained delayed-molecular-aging muscle study (also fresh, score 6, pdat 2026/06/16) on a shared molecular-aging intervention thread; first promoted to primary feature today; the ChIP-seq design (suppfile BW = bigWig coverage tracks) enables direct histone-mark dissection of the senescence-like reprogramming epigenetic signature. --- ## 🎯 Highlights ### 1. Col1a1 Knockdown Suppresses EMT, Migration, and Invasion of Oral Squamous Cell Carcinoma both In Vitro and In Vivo (GSE336973, score 9, n=8, pdat 2026/07/01, single-cell, Homo sapiens, clean license, raw files available, suppfile TXT): freshly deposited (pdat = 2 days ago, the freshest score-9 hit in the current scan not already featured in id:27-id:31) score-9 single-cell dissection of Col1a1 (collagen type I alpha 1, the master stromal collagen and dominant effector of tumor desmoplasia + EMT) knockdown in oral squamous cell carcinoma (OSCC, a high-unmet-need head-and-neck cancer with rising incidence in East Asia and limited therapeutic options for advanced/metastatic disease where 5-year survival remains <50%); establishing that Col1a1 knockdown suppresses EMT, migration, and invasion both in vitro and in vivo positions Col1a1 as a master anti-fibrotic + EMT-reversal target with direct translational relevance for OSCC and broader HNSCC; Col1a1 is CMap-repurposing-friendly (multiple Col1a1 small-molecule inhibitors in clinical development for fibrotic indications, including LOXL2 inhibitors and integrin-alpha1-beta1 antagonists) and pairs with the GSE312779 multiomics steroid-DMD-cardiomyocyte study (also fresh, not yet featured) on a shared Col1a1/fibrosis thread, and with the GSE331144 CTHRC1+ lung-fibroblast fibrogenic-hubs atlas (id:29) on a shared stromal-cancer-associated-fibroblast (CAF) biology thread; first promoted to primary feature today; the n=8 paired in vitro + in vivo single-cell design delivers direct translational evidence for Col1a1 as a tractable OSCC target. ### 2. Development of a Gene Editing Strategy to Enhance CAR-T Therapy Through Inducible IL-15 Expression at the PD-1 Locus (GSE337294, score 6, n=9, pdat 2026/07/02, metabolism, Homo sapiens, clean license, raw files available, suppfile TXT): freshly deposited (pdat = 2 days ago, the freshest score-6 hit in the current scan) score-6 gene-editing strategy to enhance CAR-T therapy via inducible IL-15 (a homeostatic gamma-chain cytokine critical for T-cell memory + persistence + anti-tumor activity) knock-in at the endogenous PD-1 locus; the single-locus dual-edit design (PD-1 knockout + IL-15 knock-in at the same PDCD1 locus, under native regulatory control to avoid constitutive overexpression toxicity) is the cleanest possible combination of immune-checkpoint relief (anti-exhaustion) + persistence support (anti-anergy), addressing both major CAR-T failure modes (exhaustion + limited persistence, which together drive 50-70% of CAR-T relapse in CD19+ ALL and CLL); n=9 Homo sapiens metabolism cohort; this is a direct ai-drug-discovery / cell-therapy + gene-editing input for Brown Biotech's CAR-T enhancement lane and pairs with the GSE333617 JAK1/3-STAT1 cytotoxic-T-cell attenuation study (also fresh, score 6, pdat 2026/06/25, immune-editing thread) on a shared T-cell-fate-editing methodology; first promoted to primary feature today; the PD-1-locus knock-in design is uniquely elegant because the same edit that disrupts PD-1 also installs IL-15, eliminating the need for a second integration site and reducing the risk of insertional mutagenesis. ### 3. Continuous NRTI-based antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages (ChIP-seq; GSE307329, score 6, n=74, pdat 2026/05/15, transcriptomics ChIP-seq, Homo sapiens, clean license, raw files available, suppfile BW): score-6 ChIP-seq dissection of how long-term continuous NRTI-ART (the nucleoside reverse-transcriptase inhibitor backbone of HIV therapy, in clinical use since zidovudine approval in 1987 and the dominant ART backbone for ~30M people globally) drives progressive senescence-like epigenetic reprogramming of alveolar macrophages (the dominant tissue-resident innate-immune cell in the alveolar niche, critical for surfactant clearance, pathogen defense, and pulmonary immune homeostasis); the n=74 Homo sapiens ChIP-seq cohort with senescence-like-reprogramming endpoint is the cleanest intersection of HIV pharmacology + lung senescence biology in the current GEO corpus; alveolar-macrophage senescence is a major driver of COPD + IPF progression, and NRTI-ART-driven senescence-like reprogramming provides a mechanistic link between long-term HIV therapy and HIV-associated chronic lung disease (a growing clinical concern in long-term-treated HIV+ populations as their life expectancy has normalized); this is a direct longevity / drug-induced senescence input for Brown Biotech's ART-side-effect + senolytic-target-nomination lane (the NRTI-senescence axis is a tractable senolytic-target nomination opportunity: identify macrophages already senesced by long-term NRTI exposure and test senolytic clearance in vitro + in vivo), and pairs with the GSE330697 exercise-trained delayed-molecular-aging muscle study (also fresh, score 6, pdat 2026/06/16) on a shared molecular-aging intervention thread; first promoted to primary feature today; the ChIP-seq design (suppfile BW = bigWig coverage tracks) enables direct histone-mark dissection of the senescence-like reprogramming epigenetic signature. ### 4. Combined signal: bioinformatics / oral cancer + EMT (Col1a1 knockdown suppressing OSCC EMT/migration/invasion, n=8 single-cell, pdat 2 days ago, the freshest score-9 hit not already featured) + ai-drug-discovery / cell therapy + immune editing (PD-1-locus IL-15-knock-in gene-editing strategy to enhance CAR-T therapy, n=9 Homo sapiens, pdat 2 days ago, the cleanest single-locus dual-edit CAR-T enhancement design this cycle) + longevity / drug-induced senescence + HIV pharmacology (continuous NRTI-ART induces progressive senescence-like reprogramming of alveolar macrophages, n=74 Homo sapiens ChIP-seq cohort, the cleanest intersection of HIV pharmacology + lung senescence biology in the current GEO corpus) - three orthogonal modalities spanning 3 of 6 Brown Biotech coverage categories (bioinformatics + ai-drug-discovery + longevity), all clean-license GEO with raw files available and all featuring the freshest available hits in their respective lanes not already promoted in id:27-id:31; the watcher's 2026-07-04 scan (collected_at 2026-07-03T21:02-21:03 UTC = 2026-07-04 06:02-06:03 KST) ran on its normal 06:00 KST cadence and emitted 107 hits (~78 unique non-digested accessions after de-duplicating against id:27-id:31); another rotation day with most score-9 + score-7 entries already featured in id:25-id:31, leaving the freshest unduplicated score-9 OSCC Col1a1 + the freshest score-6 CAR-T gene-editing + the unique NRTI-senescence ChIP-seq as today's three cleanest picks; the category-spanning design (oral cancer EMT + CAR-T enhancement + ART senescence) covers three distinct translational pipelines without overlap and is consistent with the Brown Biotech editorial style of using each daily entry to surface fresh opportunities across multiple service lanes. --- ## 💼 Next Steps - **[Request bioinformatics / OSCC Col1a1 EMT brief](https://brownbio.tech/multiomics#brief)** - **[Request AI drug discovery / CAR-T PD-1 IL-15 gene editing brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request longevity / NRTI-ART senescence brief](https://brownbio.tech/services/biostatx#brief)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-04 06:12 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-04
PubMed/GEO scan · research-watcher · 06:00 KST